News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Stocktwits Deals and strategy
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Paradigm BioCapital, along with its related entities and Senai Asefaw, M.D., has reported a collective beneficial ownership of 7.8% in Assembly Biosciences (ASMB), totaling 1,553,748 shares. This stake is based on an amended Schedule 13G filing, with Paradigm BioCapital International Fund Ltd. directly holding …
This article analyzes the price action of Assembly Biosciences Inc. (ASMB), highlighting a mid-channel oscillation pattern and a strong risk-reward short setup. It presents three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—tailored for different risk profiles, along with multi-timeframe signal analysis to …
Assembly Biosciences (NASDAQ:ASMB) saw its shares rise by 8.2% after reporting better-than-expected quarterly earnings, with a loss of $0.20 per share against an anticipated $0.72 loss and revenue of $13.37 million surpassing estimates of $8.60 million. Analysts have a "Moderate Buy" consensus rating with …
Mobileye Global Inc. announced that director Patrick Bombach resigned from its board on August 8, 2026, following his resignation from roles at Intel Corporation, its controlling shareholder. The company stated that Bombach's departure was due to governance changes at Intel and not disagreements with …
Assembly Biosciences (NASDAQ:ASMB) reported quarterly earnings, beating analyst expectations with an adjusted loss of $0.20 per share, $0.52 better than forecast, and revenue of $13.37 million, exceeding estimates of $8.60 million. Following the news, shares rose significantly by $2.89 to $29.95 on high trading …
Assembly Biosciences reported its Q2 2026 financial results, revealing a projected cash runway into 2029, bolstered by a recent $115 million financing and an anticipated $75 million payment from Gilead. The company is advancing its ABI-6250 program into Phase 2 studies for cholestatic liver …
Assembly Biosciences, Inc. – Expanded ABI-6250 clinical development into cholestatic liver diseases, including primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) – – Completed $115 million gross financing to support advancement of pipeline programs through key development milestones – – GS-1179 (formerly ABI-1179) …
Mobileye Global Inc. director Safroadu Yeboah-Amankwah purchased 11,841 shares of Class A Common Stock at $8.46 per share on August 6, 2026. This open-market transaction increased his direct holdings to 84,336 shares of Class A Common Stock. The Form 4 filing details this acquisition, …
This article highlights bullish sentiments from analysts on three NA sector companies: Versigent Limited (VGNT), SpaceX (SPCX), and Circle Internet Group, Inc. Class A (CRCL). Morgan Stanley and RBC Capital maintained Buy ratings for Versigent, Wolfe Research reiterated a Buy for SpaceX, and William …
Mobileye Director Frank D. Yeary recently purchased 12,360 shares of the company's Class A Common Stock for approximately $98,600, increasing his total equity position by 16%. This acquisition occurred after a 43% stock decline over the past year, signaling a positive outlook from the …
This article analyzes Assembly Biosciences Inc. (NASDAQ: ASMB), highlighting a weak near and mid-term sentiment but a neutral long-term outlook. It identifies a mid-channel oscillation pattern and an exceptional short setup targeting an 18.0% downside with minimal risk. The analysis also provides institutional trading …
Mobileye Global Inc. director Frank D. Yeary purchased 12,360 shares of Class A common stock at $7.98 per share on July 30, 2026. The shares were acquired indirectly through the Sea Turtle Revocable Trust, of which Yeary is the trustee. Following this transaction, Yeary …
Assembly Biosciences (ASMB) is anticipated to release its Q2 2026 earnings before market open on Wednesday, August 5th. Analysts project a loss of $0.70 per share on revenue of $8.6 million. The company previously reported a Q1 2026 loss of $0.54 per share, surpassing …
Eversept Partners LP significantly reduced its stake in Assembly Biosciences by 74.4% in the first quarter, selling 118,787 shares and retaining 40,889 shares valued at $1.14 million. Despite this, institutional investors collectively own 19.92% of the company, and analyst sentiment remains largely positive with …
Assembly Biosciences Inc (ASMB) has an institutional shareholding score of 5.00, placing it 132nd out of 384 in the Biotechnology & Medical Research industry. The institutional shareholding proportion is 58.24%, marking a 171.06% increase quarter-over-quarter. Steven Cohen is the largest institutional shareholder, holding 348.54K …
Assembly Biosciences Inc (ASMB) has a risk assessment score of 4.63, placing it 69th out of 385 in the Biotechnology & Medical Research industry. The company's beta of 1.09 indicates higher volatility compared to the S&P 500 index. The article details various risk metrics …
This article provides an overview of Assembly Biosciences Inc (ASMB) dividends and stock splits. It notes that no dividends have been distributed in the past five years and lists several merger-related stock split events that occurred on February 8, 2024, with a 12-to-1 ratio.
Mobileye Global, Inc. (MBLY) reported modest Q2 revenue growth and raised its full-year guidance, driven by strong ADAS demand. CEO and co-founder Amnon Shashua will transition to chairman as the company searches for a successor. Additionally, Mobileye secured a deal with Stellantis to supply …
This article provides a detailed cash flow statement for Assembly Biosciences Inc (ASMB), including operating, investing, and financing cash flows presented quarterly and annually. It features historical financial data stretching back to 2012, along with year-over-year percentage changes. The article also includes FAQs explaining …
The article provides an overview of market sentiment signals for Assembly Biosciences (ASMB), including analyst consensus, short interest, options flow, and recent analyst actions. It highlights a "Buy" consensus from analysts with an average price target significantly above the current stock price, increasing short …
This article provides a detailed financial overview of Assembly Biosciences Inc (ASMB), including its current stock price, market capitalization, P/E ratio, and recent performance. It also covers the company's financial health, technical indicators, analyst ratings, and a profile describing its focus on developing small-molecule …
Search by ticker symbol or company name and select a result to open its chart.